Do All Patients Deserve Treatment with Angiotensin Converting Enzyme Inhibitors after Myocardial Infarction? An Argument to Treat only High-Risk Patients

Supplements and Featured PublicationsAdvances in Cardiovascular Therapeutics: Trends in ACE Inhibition
Volume 2
Issue 1 Suppl

© 2023 MJH Life Sciences
AJMC®
All rights reserved.